Table 2 Multivariate analysis of risk factors for EBV and CMV infections
Risk factors | EBV DNAemia | EBV-associated disease | CMV DNAemia | CMV-associated diseases | ||||
|---|---|---|---|---|---|---|---|---|
HR(95%CI) | P | HR, 95%CI | P | HR, 95%CI | P | HR, 95%CI | P | |
Patient gender | ||||||||
 Male | 1 | 0.084 | 1 | 0.110 | 1 | 0.140 | 1 | 0.560 |
 Female | 0.70 (0.47–1.05) |  | 0.35(0.10–1.26) |  | 1.18 (0.95–1.48) |  | 0.71 (0.23–2.23) |  |
Patient age | ||||||||
 < 27 years | 1 | 0.570 | 1 | 0.300 | 1 | 0.003 | 1 | 0.470 |
 ≥ 27 years | 0.90 (0.63–1.29) |  | 1.58,(0.67–3.74) |  | 1.39 (1.11–1.73) |  | 0.69 (0.24–1.93) |  |
Conditioning | ||||||||
 BuCy | 1 | 0.005 | 1 | 0.061 | 1 | 0.380 | 1 | 0.420 |
 Intensified | 1.73 (1.18–2.54) |  | 2.28 (0.96–5.42) |  | 0.88 (0.67–1.17) |  | 1.55 (0.54–4.45) |  |
EBV serostatus, |  |  |  |  | – |  | – |  |
 Other | 1 | 0.046 | 1 | 0.038 |  | – |  | – |
D−/R+ | 1.58 (1.01–2.46) |  | 2.85 (1.06–7.670 |  |  |  |  |  |
CMV serostatus | – |  | – |  |  |  |  |  |
 Other |  | – |  | – | 1 | 0.420 | 1 | 0.051 |
 D−/R+ |  |  |  |  | 0.79 (0.44–1.41) |  | 4.54 (0.99–20.78) |  |
ATG dose, | ||||||||
 7.5 mg/kg | 1 | < 0.001 | 1 | 0.065 | 1 | 0.013 | 1 | 0.050 |
 10.0 mg/kg | 2.02 (1.37–2.97) |  | 2.45 (0.95–6.33) |  | 1.31 (1.06–1.62) |  | 3.65 (1.00–13.32) |  |